Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : TGL WHAAAAAAAT! Alerts, thoughts, discussion. -- Ignore unavailable to you. Want to Upgrade?

To: Kevin Clarke who wrote (123254)	11/21/2003 1:20:23 PM
From: Jim Bishop	Read Replies (1) \| Respond to of 150070

DNAP Tony on TV tonight. Nightline: Friday Night November 21, 2003 Will Air a Segment on DNA Testing And Its Dramatic Impact on Our Heritage Friday November 21, 9:50 am ET SARASOTA, Fla., Nov. 21 /PRNewswire-FirstCall/ -- Nightline, airing on ABC Friday night November 21, 2003, will discuss and review DNA testing and our perception of our heritage and what we often call 'Race.' This dramatic disclosure will feature interviews from Dr. Mark Shriver, Assistant Professor of Anthropology and Genetics at Penn State University, Dr. Tony Frudakis, Chief Scientific Officer at DNAPrint(TM) genomics, Inc. (OTC Bulletin Board: DNAP - News), and Mr. Wayne Joseph. The show will explore DNA testing and its potential impact on all of us. Watch Nightline, guaranteed to make you think! Check a local ABC affiliate for times in other time zones, but the show typically airs at 11:30 PM Eastern time, usually right after the local news. About DNAPrint(TM) genomics, Inc. DNAPrint(TM) genomics Inc. was founded by a team of scientists with research and commercial experience in high-level mathematical modeling, programming and molecular genetics. The DNAWitness(TM) and the ANCESTRYbyDNA(TM) analysis is a direct result of focused research by the DNAP research and development team. In addition, using proprietary human genome research methods, the Company develops pharma-predictive tests for matching patients with drugs based on their genetic constitution, discovers disease genes for the development of new drugs and develops new forensic genomics and consumer genomics-testing products. The Company is traded on the NASDAQ OTC Bulletin Board under the ticker symbol: DNAP. For more information about the company, please visit www.dnaprint.com . For more information on our genealogical DNA derived test, ANCESTRYbyDNA(TM) 2.0, visit us on-line at www.ancestrybydna.com , helping everyone to understand their genetic heritage. All statements in this press release that are not historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act, as amended. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's(TM) products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint(TM) genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's(TM) expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based. Media and Press Contacts Richard Gabriel DNAPrintTM genomics, Inc. CEO/President (941) 366-3400 -------------------------------------------------------------------------------- Source: DNAPrint(TM) genomics, Inc.